See the published version of this preprint at World Journal of Surgical Oncology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Systemic inflammatory parameters, such as the elevator PLR (platelet-lymphocyte ratio), have been found to be associated with the prognosis in gastric cancer (GC); however, the results remain controversial. So we aimed to evaluate the prognostic role of the PLR in gastric cancer by conducting this meta-analysis.
Methods
We performed a systematic literature search in PubMed, Embase and the Cochrane Library. The hazard ratio (HR) /Odds Ratio (OR) and its 95% confidence (CI) of survival outcomes and clinicopathological parameters were calculated.
Results
A total of 49 studies (51 cohorts) with 28,929 GC patients were included in the final meta-analysis. The pooled results showed that elevated PLR was significantly associated with poor overall survival (OS) (HR: 1.37, 95% CI: 1.26–1.49, p < 0.001; I2 = 79.90%, Ph < 0.001) and disease-free survival (DFS) (HR 1.52, 95%CI 1.22–1.90, P < 0.001, I2 = 88.6%, Ph< 0.001) of GC patients. Furthermore, patients with elevated PLR had a higher risk of lymph node metastasis (OR = 1.17, 95% CI: 1.02–1.33, p = 0.023), serosal invasion (T3 + T4) (OR = 1.34, 95% CI: 1.10–1.64, p = 0.003) and increased advanced stage (III + IV) (OR = 1.20, 95% CI: 1.06–1.37, p = 0.004).
Conclusions
This meta-analysis demonstrated that elevated PLR was a prognostic factor for poor OS and DFS, and associated with clinicopathological parameters in patients with GC.
Keywords
Platelet, Lymphocyte, PLR, Gastric Cancer, Meta-Analysis
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at World Journal of Surgical Oncology.
No community comments so far
Editorial decision: Accept
On 04 Jul, 2020
Review #2 received
Received 26 Jun, 2020
Review #1 received
Received 26 Jun, 2020
Reviewer #2 agreed
On 21 Jun, 2020
Reviewer #1 agreed
On 21 Jun, 2020
Reviewers invited
Invitations sent on 16 Jun, 2020
Editor assigned
On 15 Jun, 2020
Submission checks complete
On 14 Jun, 2020
Editor invited
On 14 Jun, 2020
Version 1
Posted 17 Apr, 2020
No comments provided
Editorial decision: Major Revision
On 06 Jun, 2020
Review #1 received
Received 27 Apr, 2020
Review #2 received
Received 27 Apr, 2020
Reviewer #2 agreed
On 16 Apr, 2020
Reviewers invited
Invitations sent on 15 Apr, 2020
Reviewer #1 agreed
On 15 Apr, 2020
Editor assigned
On 14 Apr, 2020
Submission checks complete
On 13 Apr, 2020
Editor invited
On 13 Apr, 2020
First submitted
On 11 Apr, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at World Journal of Surgical Oncology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at World Journal of Surgical Oncology.
No community comments so far
Editorial decision: Accept
On 04 Jul, 2020
Review #2 received
Received 26 Jun, 2020
Review #1 received
Received 26 Jun, 2020
Reviewer #2 agreed
On 21 Jun, 2020
Reviewer #1 agreed
On 21 Jun, 2020
Reviewers invited
Invitations sent on 16 Jun, 2020
Editor assigned
On 15 Jun, 2020
Submission checks complete
On 14 Jun, 2020
Editor invited
On 14 Jun, 2020
Version 1
Posted 17 Apr, 2020
No comments provided
Editorial decision: Major Revision
On 06 Jun, 2020
Review #1 received
Received 27 Apr, 2020
Review #2 received
Received 27 Apr, 2020
Reviewer #2 agreed
On 16 Apr, 2020
Reviewers invited
Invitations sent on 15 Apr, 2020
Reviewer #1 agreed
On 15 Apr, 2020
Editor assigned
On 14 Apr, 2020
Submission checks complete
On 13 Apr, 2020
Editor invited
On 13 Apr, 2020
First submitted
On 11 Apr, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at World Journal of Surgical Oncology.
Background
Systemic inflammatory parameters, such as the elevator PLR (platelet-lymphocyte ratio), have been found to be associated with the prognosis in gastric cancer (GC); however, the results remain controversial. So we aimed to evaluate the prognostic role of the PLR in gastric cancer by conducting this meta-analysis.
Methods
We performed a systematic literature search in PubMed, Embase and the Cochrane Library. The hazard ratio (HR) /Odds Ratio (OR) and its 95% confidence (CI) of survival outcomes and clinicopathological parameters were calculated.
Results
A total of 49 studies (51 cohorts) with 28,929 GC patients were included in the final meta-analysis. The pooled results showed that elevated PLR was significantly associated with poor overall survival (OS) (HR: 1.37, 95% CI: 1.26–1.49, p < 0.001; I2 = 79.90%, Ph < 0.001) and disease-free survival (DFS) (HR 1.52, 95%CI 1.22–1.90, P < 0.001, I2 = 88.6%, Ph< 0.001) of GC patients. Furthermore, patients with elevated PLR had a higher risk of lymph node metastasis (OR = 1.17, 95% CI: 1.02–1.33, p = 0.023), serosal invasion (T3 + T4) (OR = 1.34, 95% CI: 1.10–1.64, p = 0.003) and increased advanced stage (III + IV) (OR = 1.20, 95% CI: 1.06–1.37, p = 0.004).
Conclusions
This meta-analysis demonstrated that elevated PLR was a prognostic factor for poor OS and DFS, and associated with clinicopathological parameters in patients with GC.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...